Abstract | OBJECTIVE: METHODS: 21 cases of firstly diagnosed Ph+ALL patients aged <12 year treated with Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL 2008) protocol form January 2008 and April 2015 were retrospectively analyzed.The patients were divided into two groups, one group was TKI+ chemotherapy group, the other group was allo-HSCT group. RESULTS: Among 21 patients, 17 were male and 4 were female with a median age of 8 years old (range, 4-12 years), the median follow-up time was 30 moths (range, 10-133 months). All the patients were treated with chemotherapy induced by the high-risk project of CCLG-ALL 2008. Among 14 patients treated with TKI plus chemotherapy, nine patients achieved complete remission. During 3 months after treatment, patients without complete molecular response or with the second complete remission and intensity desire of transplantation were treated with allo-HSCT, among 9 patients with allo-HSCT, six patients achieved long term survival. CONCLUSION: At TKI era, TKI combined with strong chemotherapy can make Ph+ ALL children achieve 5 years event-free survival as campared those treated with allo-HSCT. However, for the patients without complete molecular response persistently and relapsed they can still benefit from allo-HSCT.
|
Authors | Shu-Chun Wang, Ye Guo, Xiao-Juan Chen, Xiao-Ming Liu, Min Ruan, Wen-Yu Yang, Li Zhang, Yao Zou, Yu-Mei Chen, Xiao-Fan Zhu |
Journal | Zhongguo shi yan xue ye xue za zhi
(Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Vol. 29
Issue 1
Pg. 38-42
(Feb 2021)
ISSN: 1009-2137 [Print] China |
PMID | 33554794
(Publication Type: Journal Article)
|
Chemical References |
- Protein Kinase Inhibitors
|
Topics |
- Aged
- Child
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Infant
- Male
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(therapy)
- Protein Kinase Inhibitors
- Retrospective Studies
|